Michael Dodds
Executive Director at Certara; Vice President, Quantitative Sciences at Lumen Bioscience
- Role
- Executive Director, Consulting Services at Certara
- Location
- Seattle, WA, US
- LinkedIn followers
- 500 followers
About Michael Dodds
Mike’s research focuses on the application of pharmacometrics: mathematical models of biology,(patho)-physiology, pharmacology and disease that quantify beneficial and undesirable interactions between drugs and patients to predict outcome [Barrett 2008]. Importantly, accurate and precise quantitative prediction of patient outcome allows for informed drug-development decisions. The following sections detail examples where Mike has applied pharmacometric research principals to aid in drug-development, with an emphasis on decision quality and business impact.Tools-of-the-trade:Population approach: NONMEM 7.2, PDx-Pop, Xpose, SPKGeneral purpose and custom programming: MATLAB, C++, SAS, S-Plus/RModel development: Berkeley Madonna, SAAM II, WinPOPTNoncompartmental analysis: WinNonlin (LIMS and database integration)Google Scholar Publication Tracker: https://scholar.google.com/citations?hl=en & & view_op=list_works & sortby=pubdateORCID Id:
Experience
Executive Director, Consulting Services
Oct 2015 — Present · Seattle, WA, US
Mike Dodds has been working in the pharmacometrics field since 2005. He joined Certara (formerly Quantitative Solutions) in 2015 in the role of Director Consulting Services and is based in Seattle, Washington. Previously, he worked for ZymoGenetics in the Department of Pharmacokinetics and Pharmacodynamics, providing predictive modeling support for emerging drug candidates in the areas of autoimmunity, coagulation and oncology. Prior to that, he worked for Amgen in the Department of Pharmacokinetics and Drug Metabolism and then Clinical Pharmacology Modeling and Simulation as a pharmacometrics subject matter expert, providing modeling and simulation expertise to guide development program decisions around target selection, candidate selection, preclinical-to-clinical translation, Phase 1, 2 and 3 dose and regimen selection, and biosimilar development.
Education
University of Washington
Ph.D., Bioengineering
2000 — 2004
North Carolina State University
B.S., Biochemistry
1991 — 1995
North Carolina School of Science and Mathematics
G.E.D.
1989 — 1991
North Carolina State University
B.S., Chemical Engineering
1991 — 1995
Montana State University-Bozeman
M.S., Chemical Engineering
1996 — 1998
Skills
- R
- Sas
- Drug Development
- Pharmacology
- Biotechnology
- C++
- Pk/Pd
- Modeling
- Clinical Development
- Clinical Trials
- Drug Discovery
- Programming
- Drug Metabolism
- Pharmaceutical Industry
- Fortran
- Life Sciences
- Oncology
- Pharmacokinetics
- Pharmacodynamics
- Matlab
- Data Analysis
- Ind
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.